I know I sound like a fool here on this, but Randall had called it quite a while ago, except it never reached his target of 100. I think he folded too quickly!
Actually I told you earnings would be great and they were, so name calling is not necessary. I think you are the one upset because if I remember correctly you were the one that purchased around 84 only a few weeks ago. Unfortunately for you, the stock went down, but if you actually purchased the stock like me you'd still be sitting pretty albeit not as pretty as before earnings, but so what ?
Question is did you invest in DECKERS the company or are you attempting to make a quick profit?
I you are attempting to make a quick profit you must also know then know the potential for quick loses is also great.. As for me, I continue to buy, sell and hold DECK, I held before earnings and do the same after earnings and it has rewarded me well. Yes things have changed for the company, it has come back from the dead only a year ago and is back in business and is expanding its stores, marketing more, has a clean inventory, doesn't need to discount its products. I wouldn't call that dead money. Ever heard the term you need to spend money to earn money?
As for the stock, it doesn't matter to me if it hits 70 now, because it will hit 80 soon enough and one day it will also hit 100 or 110.. and when it does, I'll be doing some buying and some selling and more holding. Everyone still forgets, this company could also get acquired.
It's called being very conservative on their guidance. You have to remember they got burned the last time they painted a somewhat rosy picture to the tune of $50. I think they never want to get caught with their pants down ever again. They will easily beat, but they want to lower expectations. Forecasting an 8% growth instead of a 21% growth is stating that they will likely have growth between the two numbers. Forecasting a -$.16 instead of a +$.10 is really negligible when they beat by $.25 anyways
So they beat by $0.25, but they projected the next quarter (report comes out in 60 days) to be a loss of $.16 instead of a gain of $.10 per share.. (Hey don't those number sound exactly the same!) Meanwhile, they move the FY from 12/31 to 3/31, so these 3 months of super cold earnings are counted where?
And the stock goes down 14%? sounds like manipulation to me.
part of their strategy.. playing guessing games. They don't know anything. Will be a 20% jump like last quarter unless DECK stays within estimate, then they'll say company does not have "stellar enough" earnings. If you look at the short numbers, they are not so high, but if DECK dare have similar earnings as estimated (around $3.8), the stock will go down back to $60. just my opinion.
my zip code is all fantasy :-)
I do really believe they won't let it go over 100 just because it's a psychological number they want to play with. I just hope their EPS is around $5
Wait I have a few--
--It's NOT cold enough! The weather didn't cooperate
--It's a FAD
--Tom Brady didn't win the Superbowl
--They are not Waterproof
--Sterne Agee and Jefferies keep pumping it and i don't believe them!
--They are not using REAL sheepskin
wait for it....
-- They are SEE THRU SHOES!
Agreed. Thanks for the rare intelligent and rational posts on this board. No need to panic, you believe in the drug, you will be rewarded.
when hiring the Chief Commercial officer.. I do believe they will pursue both the options of partnership/buyout AND commercialization---
"While we work toward the PDUFA action date for our Northera new drug application, the Company will continue to pursue a dual path of preparing for the potential commercial launch of Northera and actively assessing our strategic alternatives," said Joseph G. Oliveto, President and Chief Executive Officer of Chelsea Therapeutics. "Keith has a strong understanding of the neurogenic orthostatic hypotension orphan market, having led the team which designed our initial commercial strategies and having more recently consulted for the Company. He is ideally positioned to help execute a launch plan for Northera, as well as to support our review of strategic alternatives."